(Q34237411)

31 July 2017

1 reference

title

Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies (English)

1 reference

31 July 2017

Tabibiazar R

1

1 reference

31 July 2017

Jamali AH

series ordinal

2

1 reference

31 July 2017

Rockson SG

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

471-480

1 reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Endothelial dysfunction: from physiology to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Genetic control of blood pressure and the angiotensinogen locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Regulation of blood pressure by the type 1A angiotensin II receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

D Allele of the Angiotensin I–Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary Stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin II Type 2 Receptor Blockade Amplifies the Early Signals of Cardiac Growth Response to Angiotensin II in Hypertrophied Hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Study on the functionality and molecular properties of the AT4 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Evidence that macrophages in atherosclerotic lesions contain angiotensin II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin-Converting Enzyme Inhibitors and Insulin Sensitivity: Metabolic Effects in Hypertension, Diabetes, and Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Kinins and cardioprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Valsartan in heart failure patients previously untreated with an ACE inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Nephropathy in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effect of captopril, losartan, and bradykinin on early steps of insulin action

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900641-6

10.1016/S0002-9343(01)00641-6

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference